Solid Biosciences is evolving from a speculative Duchenne gene therapy company into a broader rare disease platform with multiple clinical programs. The company holds $380.7 million in cash, funding operations through 2028 and supporting costly Phase 3 trials for its lead candidate SGT-003, which has shown promising safety and biomarker results in early trials. Additional programs targeting Friedreich’s ataxia and CPVT expand its market potential. The company’s valuation depends on successfully translating biomarker improvements into real patient benefits, with clinical execution and competition as key risks.
First Merchants Corporation will release its financial results for the second quarter of 2026 on July 22, followed by a conference call and webcast on July 23. Investors can register to participate in the call or view the webcast online, with a repla...
The North Texas Food Bank has appointed five new board members with diverse expertise in foodservice, retail, finance, and operations, effective July 1, 2026. These leaders bring valuable experience to support the organization's growth and mission to...
First Federal Savings Bank and the Independent Community Bankers of America (ICBA) have issued 10 financial safety tips to help travelers manage their money securely during the summer travel season. Key advice includes notifying banks of travel plans...
LKQ Corporation announced it will publish its financial results for the second quarter of 2026 on July 30. The company will host a conference call and webcast with senior management to discuss the results, providing investors an opportunity to hear i...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
